【莱伯泰科股东转让6.15%股份，青岛创新投资入局】20日，莱伯泰科公告透露，持股5%以上股东 LabTechHoldings与青岛创新投资签订《股份转让协议》。LabTechHoldings拟以27.50元/股的价格，向青 岛创新投资转让4,145,454股无限售流通股，占公司股份总数的6.15%。 转让完成后，青岛创新投资将持 有4,145,454股，占比6.15%，成为持股5%以上股东。此次协议转让不会使公司控股股东、实际控制人发 生变更。 本文由 AI 算法生成，仅作参考，不涉投资建议，使用风险自担 扫码查看原文 【莱伯泰科股东转让6.15%股份,青岛创新投资入 局】20日,莱伯泰科公告透露,持股5%以上股东 LabTechHoldings与青岛创新投资签订《股份转让 协议》。LabTechHoldings 拟以27.50元/股的价 格,向青岛创新投资转让4.145.454股无限售流通 股,占公司股份总数的6.15%。转让完成后,青岛 创新投资将持有4,145,454股,占比6.15%,成为持 股5%以上股东。此次协议转让不会使公司控股股 东、实际控制人发生变更。 本文由 Al 算法生成,仅作参考,不 ...

Core Viewpoint - LabTech Holdings intends to transfer 4.1455 million shares of Leibotech (688056.SH) to Qingdao Innovation Investment at a price of 27.50 CNY per share, representing 6.15% of the company's total shares [1] Group 1 - The share transfer agreement was signed on October 20, 2025, between LabTech Holdings and Qingdao Innovation Investment [1] - After the completion of the transfer, Qingdao Innovation Investment will become a shareholder holding more than 5% of the company [1] - The transfer will not result in a change of the company's controlling shareholder or actual controller, nor will it trigger a mandatory bid or significantly impact the company's governance structure and ongoing operations [1]

Core Viewpoint - LabTech Holdings plans to transfer 4.1455 million shares of Leibotech (688056.SH) to Qingdao Innovation Investment at a price of 27.50 CNY per share, representing 6.15% of the company's total shares [1] Group 1 - The share transfer agreement was signed on October 20, 2025, between LabTech Holdings and Qingdao Innovation Investment [1] - After the transfer, Qingdao Innovation Investment will hold 4.1455 million shares, becoming a shareholder with over 5% ownership [1] - The transfer will not result in a change of the company's controlling shareholder or actual controller, nor will it trigger a mandatory bid or significantly impact the company's governance structure or ongoing operations [1]

北京莱伯泰科仪器股份有限公司 简式权益变动报告书（受让方） | 信息披露义务人： | 青岛市创新投资有限公司 | | --- | --- | | 住所及通讯地址： | 山东省青岛市崂山区苗岭路15号全球（青岛）创投风投中心2001 | | | 室 | | 股份变动性质： | 股份增加（协议转让） | 签署日期： 2025 年 10 月 20 日 1 上市公司名称： 北京莱伯泰科仪器股份有限公司 股票上市地点： 上海证券交易所 股票简称： 莱伯泰科 股票代码： 688056.SH 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》（以下简称"《证券法》"） 《上市公司收购管理办法》（以下简称"《收购管理办法》"）《公开发行证券 的公司信息披露内容与格式准则第 15 号——权益变动报告书》（以下简称"《准 则 15 号》"）等相关法律、法规和规范性文件编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人公司章程或内部规则的任何条款，或与之相冲突。 三、依据《证券法》《收购管理办法》《准则 15 号》的规定，本报告书已 全面覆盖信息披露义务人在北京莱伯 ...

北京莱伯泰科仪器股份有限公司 简式权益变动报告书（转让方） 信息披露义务人1： LabTech Holdings, Inc. 住所及通讯地址： 美国特拉华州纽卡斯尔县威明顿市橘子街1209号 信息披露义务人2： 北京莱伯泰科管理咨询有限公司 住所及通讯地址： 北京市朝阳区呼家楼（京广中心）11层商务单元1132 信息披露义务人3： 北京兢业诚成咨询服务有限公司 住所及通讯地址： 北京市顺义区空港工业区B区安庆大街6号 股份变动性质： 股份减少（协议转让） 签署日期：2025年10月20日 上市公司名称： 北京莱伯泰科仪器股份有限公司 股票上市地点： 上海证券交易所 股票简称： 莱伯泰科 股票代码： 688056.SH 信息披露义务人声明 一、信息披露义务人根据《中华人民共和国证券法》（以下简称"《证券 法》"）《上市公司收购管理办法》（以下简称"《收购管理办法》"）《公开发 行证券公司信息披露内容与格式准则第 15 号——权益变动报告书》（以下简称 "《准则 15 号》"）等相关的法律、法规及规范性文件编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不 违反信息披露义务人公司章程 ...

证券代码：688056 证券简称：莱伯泰科 公告编号：2025-036 关于公司持股 5%以上股东协议转让部分股份 暨权益变动的提示性公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 2025 年 10 月 20 日，北京莱伯泰科仪器股份有限公司（以下简称"莱伯 泰科"或"公司"或"目标公司"）持股 5%以上股东 LabTech Holdings, Inc. （以下简称"LabTech Holdings"或"转让方"）与青岛市创新投资有限公司（以 下简称"青岛创新投资"或"受让方"）共同签署了《股份转让协议》，LabTech Holdings 拟以 27.50 元/股的价格向青岛创新投资转让其持有的公司无限售流通 股 4,145,454 股，占公司股份总数的 6.15%。本次协议转让完成后，青岛创新投 资将持有公司股份 4,145,454 股，占公司股份总数的 6.15%，成为公司持股 5% 以上股东。 本次协议转让不会导致公司控股股东、实际控制人发生变更，不触及要 约收购，不会对公司治理结构及持 ...

格隆汇10月20日丨莱伯泰科(688056.SH)公布，2025年10月20日，公司持股5%以上股东LabTech Holdings 与青岛创新投资共同签署了《股份转让协议》，LabTech Holdings拟以27.50元/股的价格向青岛创新投资 转让其持有的公司无限售流通股414.55万股，占公司股份总数的6.15%。 ...

人民财讯10月20日电，莱伯泰科(688056)10月20日公告，股东LabTech Holdings,Inc.(简称"转让方")与青 岛市创新投资有限公司(简称"青岛创新投资")共同签署了《股份转让协议》，转让方拟以27.50元/股的 价格向青岛创新投资转让其持有的公司无限售流通股414.55万股，占公司股份总数的6.15%。 ...

Core Insights - The chairman of LabTech emphasizes the critical role of scientific instruments in achieving scientific breakthroughs and becoming a technology powerhouse [2] - LabTech, as one of the first companies listed on the Sci-Tech Innovation Board in China's scientific instrument industry, focuses on increasing market share in analytical instruments and providing comprehensive solutions across the entire product chain [2][3] - The scientific instrument industry is undergoing a transformation towards automation and intelligence, with Chinese brands shifting from a defensive to an offensive strategy [2][5] Company Development - Initially, LabTech aimed to survive by offering basic products that were easy to use and of high quality, such as heating plates and cooling systems [3] - Collaborations with industry giants like Siemens helped LabTech quickly establish a market presence and reduce sales costs [3] - LabTech identified an opportunity in automating sample preparation processes, becoming the first company to systematically address this area in the industry [3][4] Strategic Focus - The company aims to lead the industry by targeting high-end fields such as semiconductors, leveraging its expertise in mass spectrometry [4] - LabTech is transitioning from a sample preparation expert to a "full-chain intelligent manufacturer," providing integrated solutions from sample processing to analysis [5] - The rapid development of new fields, such as semiconductor testing, presents significant opportunities for growth, as traditional market boundaries are being broken [6] International Market Strategy - LabTech's strategy for entering international markets focuses on exploiting gaps left by international brands in sample preparation and analysis [7] - The company has established R&D and production centers abroad, aiming for a localized operational system that encompasses R&D, production, and service [8] - LabTech believes that within 5 to 10 years, Chinese brands will capture a significant share of the global high-end detection instrument market, with aspirations to become a leading mass spectrometry brand [8]

Core Viewpoint - The article discusses the critical role of fundraising investment projects (募投项目) in corporate development, highlighting the delays and terminations faced by several companies in the industry due to various factors [1][3]. Summary by Company 普源精电 (Puyuan Precision Electric) - The company announced a delay in the "Shanghai R&D Center Construction Project" to April 2026 due to changes in the implementation method and the late completion of the new building [4][5]. 高华科技 (Gaohua Technology) - The "Gaohua R&D Capability Construction Project" has been postponed to June 30, 2026, due to tight operating funds before the IPO and the establishment of two new subsidiaries affecting the project timeline [6]. 莱伯泰科 (Leibotai Technology) - The timeline for the "Trace and Ultra-trace Element Analysis ICP-MS and Online Analysis System Production and R&D Project" has been extended to September 2026, influenced by evolving user demands and market conditions [7][8]. 迈拓股份 (Maituo Co., Ltd.) - The "Ultrasonic Measuring Instrument Production Base Construction Project in Nanjing" is delayed until December 31, 2025, due to delays in obtaining construction permits and other unforeseen factors [9][10]. 智能自控 (Intelligent Control) - The company decided to extend the timeline for its fundraising projects due to changes in the macroeconomic environment and market conditions, affecting project completion [11]. 碧兴物联 (Bixing IoT) - The "Smart Ecological Environment Big Data Service Project" and "Smart Water Big Data Traceability Analysis Service Project" have been postponed to August 2026, with no changes to the project scope or funding [12][13]. 煜邦电力 (Yubang Electric) - The company has terminated certain sub-projects and extended the timeline for remaining projects to December 2026, citing increased competition and market conditions [14][15]. 天罡股份 (Tiangang Co., Ltd.) - The "IoT Smart Ultrasonic Measuring Instrument Industrialization Project" and "R&D Center Upgrade Construction Project" have been postponed to June 30, 2026, due to equipment procurement delays and project adjustments [17][18].